Edition:
United States

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

11.69USD
17 Jul 2018
Change (% chg)

-- (--)
Prev Close
$11.69
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
199,954
52-wk High
$14.45
52-wk Low
$2.54

Chart for

About

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from... (more)

Overall

Beta: 1.73
Market Cap(Mil.): $626.90
Shares Outstanding(Mil.): 52.86
Dividend: --
Yield (%): --

Financials

  FATE.OQ Industry Sector
P/E (TTM): -- 214.90 33.15
EPS (TTM): -1.04 -- --
ROI: -62.92 -3.85 13.23
ROE: -72.89 -5.38 15.27

BRIEF-Fate Therapeutics Qtrly Loss Per Share $0.27

* FATE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

May 10 2018

BRIEF-Fate Therapeutics Files For Mixed Shelf Of Up To $150 Million

* FATE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text: (https://bit.ly/2KD5gGz) Further company coverage:

May 04 2018

BRIEF-Fate Therapeutics Announces Additional Clinical Data From Phase 1 Stage Of Protect Clinical Trial Of Protmune

* FATE THERAPEUTICS ANNOUNCES ADDITIONAL CLINICAL DATA FROM PHASE 1 STAGE OF PROTECT CLINICAL TRIAL OF PROTMUNE™

Mar 19 2018

BRIEF-Fate Therapeutics Q4 Loss Per Share $0.29​

* FATE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

Mar 05 2018

Earnings vs. Estimates